Registration and prospectus / Bone Biologics Corporation | Tables in SEC filings

BBLG Bone Biologics Corporation

IPO registration (amended)

4.4	Warrant Agent Agreement between the Company and Equiniti Trust Company dated as of October 7, 2022	8-K	001-40899	4.1	October 11, 2022

4.5	Form of Series A Warrant (October 2022)	S-1	333-276771	4.5	January 30, 2024

4.6	Form of Series B Warrant (October 2022)	S-1	333-276771	4.6	January 30, 2024

4.7	Form of Series C Warrant (October 2022)	S-1	333-276771	4.7	January 30, 2024

4.8	Form of Representative’s Warrant (October 2022)	8-K	001-40899	1.1	October 11, 2022

4.9	Form of Warrant (November 2023)	S-3	333-276412	4.1	January 5, 2024

4.10	Form of Placement Agent Warrant (November 2023)	8-K	001-40899	4.2	November 20, 2023

4.11	Form of Warrant	S-1/A	333-276771	4.11	February 23, 2024

4.12	Form of Pre-Funded Warrant	S-1/A	333-276771	4.12	February 23, 2024

4.13	Form of Placement Agent Warrant	S-1/A	333-276771	4.13	February 23, 2024

5.1	Opinion of Harter Secrest & Emery LLP	S-1/A	333-276771	5.1	February 23, 2024

10.1+	Director Offer Letter, dated July 1, 2014, by and between Bruce Stroever and Bone Biologics Corporation	8-K	000-53078	10.4	September 25, 2014

10.2+	Form of Indemnification Agreement	S-1	333-276771	10.2	January 30, 2024

10.3+	Chief Operating Officer Employment agreement, dated June 8, 2015, by and between Bone Biologics Corporation and Jeffrey Frelick	10-Q	000-53078	10.2	August 14, 2015

10.4+	Employment Agreement dated December 17, 2021 between the Company and Deina Walsh	8-K	001-40899	10.1	December 22, 2021

10.5+	Form of Professional Services Agreement, dated January 8, 2016, by and between the Company and the Founders	8-K	000-53078	10.1	January 11, 2016

10.6+	Bone Biologics Corporation Non-Employee Director Compensation Policy	8-K	000-53078	10.1	January 4, 2016

10.7+	Bone Biologics Corporation 2015 Equity Incentive Plan	8-K	000-53078	10.3	January 4, 2016

10.8+	First Amendment to the Bone Biologics Corporation 2015 Equity Incentive Plan	Schedule 14A	001-40899	Appendix B	August 3, 2023

10.9+	Form of Stock Option Grant Notice and Option Agreement for the Bone Biologics Corporation 2015 Equity Incentive Plan	8-K	000-53078	10.4	January 4, 2016

10.10+	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement	8-K	000-53078	10.5	January 4, 2016

10.11	Option Agreement for the Distribution and Supply of Sygnal™ dated as of February 24, 2016	8-K	000-53078	10.3	February 26, 2016

10.12	Amended and Restated Exclusive License Agreement, dated as of March 21, 2019, by and between the Company and The Regents of the University of California	8-K	000-53078	10.1	April 16, 2019

Exhibit		Incorporated by reference (unless otherwise indicated)
Number	Exhibit Title		Form	File	Exhibit	Filing date

2.1	Agreement and Plan of Merger, dated as of September 19, 2014, by and among AFH Acquisition X, Inc., Bone Biologics Acquisition Corp., and Bone Biologics, Inc.		8-K	000-53078	2.1	September 25, 2014

2.2	Certificate of Merger as filed with the California Secretary of State effective September 19, 2014		8-K	000-53078	2.2	September 25, 2014

3.1	Amended and Restated Certificate of Incorporation of Bone Biologics Corporation		8-K	000-53078	3.1(i)	September 25, 2014

3.2	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bone Biologics Corporation		8-K	000-53078	3.1	October 15, 2021

3.3	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bone Biologics Corporation		8-K	001-40899	3.1	June 6, 2023

3.4	Certificate of Amendment to Amended and Restated Certificate of Incorporation of Bone Biologics Corporation		8-K	001-40899	3.1	December 18, 2023

3.5	Amended and Restated Bylaws of Bone Biologics Corporation		8-K	001-40899	3.1	March 8, 2022

3.6	Amendment No. 1 to the Amended and Restated Bylaws of Bone Biologics Corporation		8-K	001-40899	3.1	October 24, 2023

4.1	Warrant Agent Agreement between the Company and Equiniti Trust Company dated as of October 13, 2021		8-K	000-53078	4.1	October 15, 2021

4.2	Form of Warrant (October 2021)		S-1	333-276771	4.2	January 30, 2024

4.3	Form of Representative’s Warrant (October 2021)		8-K	000-53078	1.1	October 15, 2021

10.13	First Amendment to the Amended License Agreement dated August 13, 2020 between the Company and the Regents of the University of California	S-1/A	333-257484	10.40	October 7, 2021

10.14	Third Amendment to the Amended License Agreement dated June 8, 2022 between the Company and the Regents of the University of California	8-K	001-40899	10.1	June 9, 2022

10.15	Supply and Development Support Agreement dated March 3, 2022 between the Company and Musculoskeletal Transplant Foundation, Inc.	10-K	001-40899	10.30	March 15, 2022

10.16	Securities Purchase Agreement (November 2023)	S-3/A	333-276412	99.1	January 17, 2024

10.17	Form of Securities Purchase Agreement	S-1/A	333-276771	10.17	February 23, 2024

10.18*	Engagement Agreement between H.C. Wainwright & Co., LLC and the Company dated October 30, 2023	—	—	—	—

10.19*	Amendment No. 1 to Engagement Agreement between H.C. Wainwright & Co., LLC and the Company dated February 6, 2024	—	—	—	—

21.1	List of Subsidiaries	8-K	000-53078	21.1	September 25, 2014

23.1	Consent of Independent Registered Public Accounting Firm, Weinberg & Company, P.A.	S-1/A	333-276771	23.1	February 23, 2024

23.2	Consent of Harter Secrest & Emery LLP (included in Exhibit 5.1)	S-1/A	333-276771	5.1	February 23, 2024

24.1	Power of Attorney (included on the signature page to the Company's Registration Statement on Form S-1)	S-1	333-276771	4.2	January 30, 2024

101.INS*	Inline XBRL Instance Document	—	—	—	—

101.SCH*	Inline XBRL Taxonomy Extension Schema Document	—	—	—	—

101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document	—	—	—	—

101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document	—	—	—	—

101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document	—	—	—	—

101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document	—	—	—	—

104	Cover Page formatted in Inline XBRL and contained in Exhibit 101

107	Filing Fee Table	S-1	333-276771	107	January 30, 2024

	Amount to be paid
SEC registration fee	$	1,531.35
FINRA filing fee		2,056.25
Transfer agent and registrar fees		20,000.00
Accounting fees and expenses		25,000.00
Legal fees and expenses		120,000.00
Printing and engraving expenses		15,000.00
Miscellaneous		-
Total	$	183,587.60

	As of December 31, 2023
	Actual		Pro Forma
Cash	$	3,026,569	$	7,292,031

Total Liabilities		831,402		831,402

Stockholders’ Equity
Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at December 31, 2023		—		—
Common stock, $0.001 par value per share; 100,000,000 shares authorized; 534,238 shares issued and outstanding at December 31, 2023; 1,816,289 shares issued and outstanding on a pro forma basis		534		1,816
Additional paid in capital		83,814,785		88,078,965
Accumulated Deficit		(80,908,958)		(80,908,958)
Total stockholders’ equity		2,906,361		7,171,823
Total capitalization	$	3,737,763	$	8,003,225

Table search / Registration and prospectus / Bone Biologics Corporation

50 results

Top filers

Top filing types

Recent filing years